Latest Docetaxel Stories
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S.
Conference call to be held on Wednesday, April 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
BOTHELL, Wash. and VANCOUVER, British Columbia, April 28, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY trial.
Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash.
TOKYO and SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Medivation Inc.
TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc.
-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb.
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
The Majority of Current Non-Prescribers Anticipate Prescribing Xofigo within the Next Year, According to Findings from Decision Resources Group BURLINGTON, Mass., Feb.
Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA